Quantinuum’s (NASDAQ:QNT – Get Free Report) quiet period is set to expire on Tuesday, July 14th. Quantinuum had issued 28,000,000 shares in its initial public offering on June 4th. The total size of the offering was $1,680,000,000 based on an initial share price of $60.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Wall Street Analysts Forecast Growth
QNT has been the topic of several research reports. Needham & Company LLC assumed coverage on shares of Quantinuum in a research note on Monday, June 29th. They set a “buy” rating and a $100.00 price objective on the stock. Evercore assumed coverage on Quantinuum in a research note on Monday, June 29th. They issued an “outperform” rating and a $98.00 price target on the stock. Jefferies Financial Group started coverage on Quantinuum in a research note on Monday, June 29th. They set a “buy” rating and a $90.00 price objective for the company. Cantor Fitzgerald initiated coverage on Quantinuum in a report on Monday, June 29th. They set an “overweight” rating and a $90.00 price target for the company. Finally, Rosenblatt Securities initiated coverage on Quantinuum in a research report on Monday, June 29th. They issued a “buy” rating and a $155.00 price target for the company. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Quantinuum has an average rating of “Moderate Buy” and a consensus price target of $98.75.
Read Our Latest Stock Report on Quantinuum
Quantinuum Stock Performance
Insider Activity at Quantinuum
In other Quantinuum news, Director Kenneth D. Denman acquired 14,000 shares of Quantinuum stock in a transaction that occurred on Friday, June 5th. The stock was bought at an average cost of $60.00 per share, for a total transaction of $840,000.00. Following the acquisition, the director owned 19,833 shares of the company’s stock, valued at $1,189,980. This represents a 240.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kevin Scott Dehoff bought 15,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was acquired at an average cost of $60.00 per share, with a total value of $900,000.00. Following the transaction, the insider owned 126,460 shares in the company, valued at $7,587,600. The trade was a 13.46% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 411,032 shares of company stock valued at $24,661,920 over the last three months.
Quantinuum Company Profile
Quantinuum is a quantum computing company focused on developing hardware and software for commercial and scientific applications. The company provides access to its quantum systems, along with software tools and services designed to help customers explore use cases in areas such as optimization, materials science, chemistry, cybersecurity, and machine learning.
The company was formed through the combination of Honeywell Quantum Solutions and Cambridge Quantum in 2021. Quantinuum operates internationally and serves a range of customers across enterprise, government, and research markets.
Recommended Stories
- Five stocks we like better than Quantinuum
- How TeraWulf’s Anthropic Deal Booted Up a $19B AI Empire
- Small-Cap ETFs Poised for Big Growth as Rate Outlook Shifts
- Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
Receive News & Ratings for Quantinuum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantinuum and related companies with MarketBeat.com's FREE daily email newsletter.
